Use of flecainide in combination antiarrhythmic therapy in patients with arrhythmogenic right ventricular cardiomyopathy.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Antiarrhythmic therapy is commonly used for suppression of arrhythmias in patients with arrhythmogenic right ventricular cardiomyopathy (ARVC) in conjunction with implantable cardioverter-defibrillators and catheter ablation. The efficacy of combination flecainide and sotalol/metoprolol therapy for patients refractory to single agents and/or catheter ablation has not been well established.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Heart Rhythm

Title: Heart rhythm

Publisher: Elsevier BV

ISSN (Electronic): 1556-3871

ISSN (Print): 1547-5271

Publication date (Electronic): Apr 2017

Volume: 14

Issue: 4

Affiliations

[1 ] Division of Cardiovascular Medicine, University of California-San Francisco, San Francisco, California. Electronic address: Simon.Ermakov@ucsf.edu.

[2 ] Division of Cardiovascular Medicine, University of California-San Francisco, San Francisco, California.

Article

Publisher Item ID: S1547-5271(16)31166-3

DOI: 10.1016/j.hrthm.2016.12.010

PubMed ID: 27939893

Data availability:

Keywords: Ventricular arrhythmia, Antiarrhythmic therapy, Arrhythmogenic right ventricular cardiomyopathy, Clinical electrophysiology, Combination therapy

Comments

Comment on this article

Cited by 12

See all cited by